Soleno Therapeutics (SLNO) Preferred Stock Liabilities (2016)
Historic Preferred Stock Liabilities for Soleno Therapeutics (SLNO) over the last 4 years, with Q4 2016 value amounting to $13.0.
- Soleno Therapeutics' Preferred Stock Liabilities rose 16000.0% to $13.0 in Q4 2016 from the same period last year, while for Dec 2016 it was $13.0, marking a year-over-year increase of 16000.0%. This contributed to the annual value of $13.0 for FY2016, which is 16000.0% up from last year.
- Latest data reveals that Soleno Therapeutics reported Preferred Stock Liabilities of $13.0 as of Q4 2016, which was up 16000.0% from $5.0 recorded in Q4 2015.
- In the past 5 years, Soleno Therapeutics' Preferred Stock Liabilities ranged from a high of $15.4 million in Q4 2013 and a low of $5.0 during Q4 2015
- Over the past 4 years, Soleno Therapeutics' median Preferred Stock Liabilities value was $7.7 million (recorded in 2014), while the average stood at $7.7 million.
- Data for Soleno Therapeutics' Preferred Stock Liabilities shows a peak YoY increase of 16000.0% (in 2016) and a maximum YoY decrease of 16000.0% (in 2016) over the last 5 years.
- Soleno Therapeutics' Preferred Stock Liabilities (Quarter) stood at $15.4 million in 2013, then decreased by 0.0% to $15.4 million in 2014, then tumbled by 100.0% to $5.0 in 2015, then skyrocketed by 160.0% to $13.0 in 2016.
- Its Preferred Stock Liabilities was $13.0 in Q4 2016, compared to $5.0 in Q4 2015 and $15.4 million in Q3 2014.